Study summary
Combining a bispecific antibody with daratumumab nearly eliminated progression for most people
83.4%progression-free at 36 months, vs 29.7% with standard treatment
What was tested
Teclistamab plus daratumumab, against daratumumab with standard chemotherapy, for myeloma after 1 to 3 earlier treatments.
What they found
- At 3 years, 83.4% were progression-free vs 29.7%.
- A complete response or better occurred in 81.8% vs 32.1%.
- No detectable cancer cells (MRD-negative) in 58.4% vs 17.1%.
What it means
One of the largest progression-free survival gains reported in myeloma; approved under the FDA's priority voucher program.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.